natgillin/translations-raw huggingface dataset:
Two representatives of the Board, Walter Schwerdtfeger and Lisette Tiddens, were appointed to the steering group set up by the European Commission to provide support to the implementation of arrangements in the area of traceability of tissues and cells.
Dva predstavnika odbora, Walter Schwerdtfeger in Lisette Tiddens, sta bila imenovana za člana usmerjevalne skupine, ki jo je Evropska komisija ustanovila za zagotavljanje podpore pri uresničevanju dogovorov na področju sledljivosti tkiv in celic.
The group will aim to propose a draft for discussion at the December 2011 meeting.
Skupina namerava osnutek predložiti v razpravo na seji decembra 2011.
Management Board Members of the European Centre for Disease Prevention and Control (ECDC) and representatives of national competent authorities (NCAs) also participate in the work of the group.
Pri delu skupine so sodelovali tudi člani upravnega odbora Evropskega centra za preprečevanje in obvladovanje bolezni (ECDC) in predstavniki nacionalnih pristojnih organov.
The Board thanked the topic coordinators (Christina Åkerman, Aginus Kalis, Jytte Lyngvig, Marcus Müllner, Giuseppe Nisticó and Lisette Tiddens) for their role in preparing this document.
Odbor se je zahvalil tematskim koordinatorjem (Christina Åkerman, Aginus Kalis, Jytte Lyngvig, Marcus Müllner, Giuseppe Nisticó in Lisette Tiddens) za njihovo vlogo pri pripravi tega dokumenta.
• The review of the legislation on veterinary medicinal products (the proposal will be made as a package with the legislation on medicated feed; the timeline for the proposal is to be set).
• sprememba zakonodaje o zdravilih za uporabo v veterinarski medicini (predlog bo predložen kot paket z zakonodajo o medicirani krmi; rok za predlog je treba še določiti);
EudraVigilance status report for veterinary medicinal products
Poročilo o stanju sistema EudraVigilance za zdravila za uporabo v veterinarski medicini
The Management Board topic coordinators Xavier De Cuyper (Belgium), Walter Schwerdtfeger (Germany) and Lisette Tiddens (Vice-chair) are revising the conflicts of interests policy applicable to the Board.
Tematski koordinatorji upravnega odbora Xavier De Cuyper (Belgija), Walter Schwerdtfeger (Nemčija) in Lisette Tiddens (podpredsednica) pregledujejo politiko o navzkrižju interesov, ki velja za odbor.
• Wednesday, 21 March & Thursday, 22 March;
• sreda, 21. marec, in četrtek, 22. marec;
This is the last meeting of the Board for Andreas Pott in his capacity as the Acting Executive Director of the Agency.
To je zadnja seja odbora, na kateri bo Andreas Pott opravljal mandat vršilca dolžnosti izvršnega direktorja agencije.
• Amendments of the fee regulation to include fees foreseen in the pharmacovigilance legislation (a European Commission proposal is expected later in 2012.
• sprememba uredbe o pristojbinah, tako da bo vključevala pristojbine, predvidene v zakonodaji o farmakovigilanci (predlog Evropske komisije je pričakovati pozneje v letu 2012.
Members of the group are: Björn Lemmer, Jytte Lyngvig, Guido De Clercq and Vincenzo Salvatore.
Člani te skupine so: Björn Lemmer, Jytte Lyngvig, Guido De Clercq in Vincenzo Salvatore.
• Thursday, 13 December.
• četrtek, 13. december.
The Management Board noted the presentation on the implementation of the policies on conflicts of interests for experts and for staff.
Upravni odbor se je seznanil s predstavitvijo o izvajanju politik o navzkrižju interesov za strokovnjake in osebje.
Historically, a complex governance structure, loss of knowledge during the implementation phase, loss of continuity between projects and inadequate representation of business users were among the negative factors that partly affected delivery of projects.
V preteklosti so na uresničitev projektov delno vplivali negativni dejavniki, kot so zapletena struktura vodenja, izguba znanja med fazo izvajanja, izguba stalnosti med projekti in nezadostna zastopanost poslovnih uporabnikov.
Members were asked to declare any specific interests that could be considered to be prejudicial to their independence with respect to the items on the agenda.
Člani odbora so bili pozvani, naj se izrečejo o kakršnih koli posebnih interesih v zvezi s katero koli točko dnevnega reda, ki bi lahko vplivali na njihovo neodvisnost.
• HMA work in the area of support to innovation (health technology assessment, discussions on medical devices and the impact of the recast of the related legislation).
• delom vodij agencij za zdravila na področju podpore inovacijam (ocena zdravstvene tehnologij, razprave o medicinskih pripomočkih in učinek prenovitve s tem povezane zakonodaje);
The situation is such that it becomes increasingly difficult for the committee to achieve its work targets, despite the action plan that had been put in place earlier.
Odbor namreč kljub akcijskemu načrtu, ki je bil sprejet pred tem, vedno težje dosega svoje delovne cilje.
• [EMA/MB/730141/2011] Summary of transfers of appropriations in the budget 2011.
• [EMA/MB/730141/2011] Povzetek prenosov dodeljenih sredstev v proračun za leto 2011.
The objectives of the meeting were to address strategic issues requiring HMA orientation, with particular focus on challenging aspects impacting on the NCAs; and to raise awareness on specific areas.
Cilj seje je bila obravnava strateških vprašanj, ki zahtevajo smernice vodij agencij za zdravila, s posebnim poudarkom na težavnih vidikih, ki vplivajo na nacionalne pristojne organe, in ozaveščanje o posebnih področjih.
Management Board meeting dates
Datumi sej upravnega odbora
The Management Board noted the update on a number of items, including the following.
Upravni odbor se je seznanil s posodobljenimi informacijami o več temah, vključno z naslednjim:
[EMA/MB/751210/2011] The Management Board appointed Sir Kent Woods as a member of the Management Board Telematics Committee following the departure of Pat O'Mahony from the committee earlier this year.
[EMA/MB/751210/2011] Upravni odbor je imenoval Kenta Woodsa za člana Odbora upravnega odbora za telematiko po odhodu Pata O'Mahonyja iz odbora v začetku tega leta.
Management Board decision-making process
Postopek sprejemanja odločitev v upravnem odboru
Rannveig Gunnarsdóttir (Iceland) Brigitte Batliner (Liechtenstein) Apologies from Norway
Rannveig Gunnarsdóttir (Islandija) Brigitte Batliner (Lihtenštajn)
• [EMA/MB/714970/2011] Outcome of written procedures during the period from 17 May 2011 to 14
• [EMA/MB/714970/2011] Rezultat pisnih postopkov v obdobju od 17. maja 2011 do 14. septembra 2011.
7bis EU telematics projects report
Telematski projekti EU
• [EMA/MB/793451/2011] EU telematics Operations Report.
• [EMA/MB/793451/2011] Poročilo o telematskih operacijah EU.
Membership of the Management Board Telematics Committee
Članstvo v Odboru upravnega odbora za telematiko.
Highlights from the Acting Executive Director
Poudarki vršilca dolžnosti izvršnega direktorja
• Thursday, 4 October;
• četrtek, 4. oktober;
EMA mid-year report 2011 from the Acting Executive Director (January - June 2011)
Vmesno poročilo agencije EMA za leto 2011, ki ga je pripravil vršilec dolžnosti izvršnega direktorja (januarjunij 2011)
[EMA/MB/376489/2011] The Management Board adopted the following meeting dates in 2012:
[EMA/MB/376489/2011] Upravni odbor je sprejel naslednje datume sej v letu 2012:
Review of meeting practices
Pregled prakse na sejah
[EMA/MB/746083/2011] The Management Board discussed whether to review the decision-making process in cases where there is evidence of a lack of consensus.
[EMA/MB/746083/2011] Upravni odbor je razpravljal o tem, ali naj prouči postopek sprejemanja odločitev, kadar je očitno, da soglasja ni mogoče doseči.
[EMA/MB/742275/2011; EMA/MB/751326/2011; EMA/MB/742295/2011; EMA/MB/752482/2011] The Management Board adopted the following implementing rules:
[EMA/MB/742275/2011; EMA/MB/751326/2011; EMA/MB/742295/2011; EMA/MB/752482/2011] Upravni odbor je sprejel izvedbena pravila za naslednja področja:
• HMA paper published in the context of the review of the veterinary legislation.
• dokumentom vodij agencij za zdravila, ki je bil objavljen v okviru spreminjanja veterinarske zakonodaje;
• Thursday, 7 June;
• četrtek, 7. junij;
Minutes from the 72nd meeting, held on 8-9 June 2011
Zapisnik 72. seje, ki je potekala 8. in 9. junija 2011
[EMA/MB/744682/2011] The Management Board noted the regular update report on the status of implementation of the European database for the collection of adverse events related to veterinary medicines.
[EMA/MB/744682/2011] Upravni odbor se je seznanil z rednim posodobljenim poročilom o stanju pri uvajanju evropske podatkovne zbirke za zbiranje neželenih učinkov, povezanih z zdravili za uporabo v veterinarski medicini.
• No 08/2011 - the appointment of Janne Komi as CHMP member, proposed by Finland, finalised on 14 July 2011.
• Št. 08/2011 - imenovanje Janneja Komija za člana odbora CHMP na predlog Finske, ki je bilo končano 14. julija 2011.
The Board appointed Guido Rasi as Executive Director of the Agency.
Odbor je imenoval Guida Rasija za izvršnega direktorja agencije.
• No 09/2011 - the appointment of Michel Tougouz Nevessignsky as CHMP alternate, proposed by Belgium, finalised on 9 September 2011.
• Št. 09/2011 - imenovanje Michela Tougouza Nevessignskyja za nadomestnega člana odbora CHMP na predlog Belgije, ki je bilo končano 9. septembra 2011.
[EMA/MB/744342/2011; EMA/MB/24913/2005/rev.1] The Management Board adopted the revised criteria that have to be fulfilled by patients' and consumers' organisations involved in EMA activities.
[EMA/MB/744342/2011, EMA/MB/24913/2005/rev.1] Upravni odbor je sprejel spremenjena merila, ki jih morajo izpolnjevati organizacije bolnikov in potrošnikov, vključene v dejavnosti agencije EMA.
[EMA/MB/729369/2011] The Management Board reinstated Gerard O'Malley as the Agency's accounting officer, effective 6 October 2011, following his return from long-term absence.
[EMA/MB/729369/2011] Upravni odbor je 6. oktobra 2011 na mesto računovodje agencije po dolgotrajni odsotnosti znova postavil Gerarda O'Malleya.
[EMA/MB/465305/2011] The Management Board noted the final minutes, adopted by written procedure on 11 August 2011.
[EMA/MB/465305/2011] Upravni odbor se je seznanil s končnim zapisnikom, ki je bil sprejet s pisnim postopkom 11. avgusta 2011.
[EMA/MB/743894/2011; EMA680110/2011] The Management Board noted the report on the implementation of the MUMS policy.
[EMA/MB/743894/2011; EMA680110/2011] Upravni odbor se je seznanil s poročilom o izvajanju politike MUMS.
[EMA/MB/744981/2011; EMA/632696/2011] The Management Board noted the report on the interactions with patients' and consumers' organisations within the framework agreed in 2005.
[EMA/MB/744981/2011, EMA/632696/2011] Upravni odbor se je seznanil s poročilom o sodelovanju z organizacijami bolnikov in potrošnikov v okviru, ki je bil dogovorjen v letu 2005.
[EMA/MB/550544/2011] The Management Board endorsed the implementation plan for the 'Road map to 2015'.
[EMA/MB/550544/2011] Upravni odbor je potrdil izvedbeni načrt za „časovni načrt agencije EMA do leta 2015“.
• No 07/2011 - the appointment of Helder Mota-Filipe as CHMP alternate, proposed by Portugal, finalised on 5 July 2011.
• Št. 07/2011 - imenovanje Helderja Mota-Filipeja za nadomestnega člana odbora CHMP na predlog Portugalske, ki je bilo končano 5. julija 2011.
[EMA/MB/793453/2011] The Management Board noted the report on the implementation of telematics projects.
[EMA/MB/793453/2011] Upravni odbor se je seznanil s poročilom o izvajanju telematskih projektov.
EMA/MB/828587/2011 Adopted Management Board
EMA/511034/2012 sprejet Upravni odbor
Minutes of the 73rd meeting of the Management Board
Zapisnik 73. seje upravnega odbora
3bis Appointment of Guido Rasi as Executive Director
Imenovanje Guida Rasija za izvršnega direktorja
• [EMA/MB/711444/2011; EMA/MB/711456/2011; EMA/MB/711459/2011] Minutes from the
• [EMA/MB/711444/2011; EMA/MB/711456/2011; EMA/MB/711459/2011] Zapisniki marčevske, majske in junijske seje odbora upravnega odbora za telematiko (MBTC).
rd meeting of the Management Board, held in London on 6 October 2011
Seznam udeležencev 73. seje upravnega odbora v Londonu 6. oktobra 2011
• HMA initiatives in the area of clinical trials in the context of the review of clinical trials legislation
• pobudami vodij agencij za zdravila na področju kliničnih preskušanj v okviru spremembe zakonodaje o kliničnih preskušanjih (postopek prostovoljnega usklajevanja);
The Agency is on track to implement agreed objectives.
Uresničevanje sprejetih ciljev v agenciji poteka po načrtih.
[EMA/MB/653974/2011] The Management Board noted the mid-year report 2011.
[EMA/MB/653974/2011] Upravni odbor se je seznanil z vmesnim poročilom za leto 2011.
An exercise to define commercially confidential information is ongoing, in cooperation with the HMA.
V sodelovanju z vodji agencij za zdravila se trenutno opredeljujejo poslovno zaupne informacije.
Representative of doctors' organisations
Predstavnik zdravniških organizacij
• Written procedure for adoption of the draft minutes of the 72
• Pisni postopek za sprejetje osnutka zapisnika 72. seje upravnega odbora, ki je bil sprejet 10. avgusta 2011.
Personnel matter
Osebje
Date of first authorisation: 01 October 2009 Date of latest renewal: 18 July 2014
Datum prve odobritve: 01. oktober 2009 Datum zadnjega podaljšanja: 18. julij 2014
• if you are taking insulin.
• če jemljete insulin.
Never take two doses on the same day.
Nikdar ne vzemite dveh odmerkov na isti dan.
This is to help keep your blood sugar under control.
To omogoča ohranjati vaš krvni sladkor pod nadzorom.
• if you have or have had a disease of the pancreas;
• če imate ali ste kdaj imeli bolezen pankreasa (trebušne slinavke),
-0.6 (evening)
-0,6 (zvečer)
In particular, you should tell your doctor if you are using medicines containing any of the following active substances:
Še zlasti morate zdravniku povedati, če uporabljate zdravila, ki vsebujejo katero od naslednjih učinkovin:
• if you have moderate or severe liver problems.
• če imate zmerne ali hude težave z jetri.
n=Randomised patients (primary efficacy-intention-to-treat analysis) with data available.
n = Randomizirani bolniki (primarna učinkovitost - analiza populacije z namenom zdravljenja) s podatki, ki so na voljo.
Swallow the tablet whole with some water.
Tableto zaužijte celo z nekaj vode.
The tablet can be taken at any time of the day, however, try to take your tablet at the same time each day.
Tableto lahko vzamete ob katerem koli času dneva, vendar jo po možnosti vzemite vsak dan ob istem času.
The safety and efficacy of Onglyza in children aged birth to < 18 years have not yet been established.
Učinkovitost in varnost zdravila Onglyza pri otrocih od rojstva do starosti < 18 let še nista ugotovljeni.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to 1/100), rare (≥ 1/10,000 to 1/1,000), very rare (< 1/10,000), or not known (cannot be estimated from the available data).
Pogostnosti so opredeljene takole: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) ali neznana (ni mogoče oceniti na podlagi razpoložljivih podatkov).
You can take the tablet with or without food.
Tableto lahko vzamete s hrano ali brez nje.
Elderly patients (65-80 years) had about 60% higher saxagliptin AUC than young patients (18-40 years).
Starejši bolniki (65-80 let) so imeli AUC približno 60 % večjo kot mladi (18-40 let).
• as monotherapy when metformin is inappropriate due to intolerance or contraindications
• kot monoterapija, ko metformin ni primeren zaradi neprenašanja ali kontraindikacij;
decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy to the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
• if you have a condition that reduces your defence against infections, such as a disease like AIDS, or from medicines that you might take after an organ transplant;
• če imate kakšno stanje, ki vam zmanjšuje obrambo pred okužbami, npr. bolezen, kakršna je AIDS, ali prejemate zdravila, kakršna se uporabljajo po presaditvi organa,
• Very common: low blood sugar (hypoglycaemia)
• Zelo pogosti: nizek krvni sladkor (hipoglikemija).
Onglyza is not recommended for children and adolescents under 18 years.
Zdravilo Onglyza ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
7.9 -0.7 (morning)
-0,7 (zjutraj)
• if you have had a serious allergic reaction to any other similar medicines that you take to control your blood sugar.
- če ste kdaj imeli resno alergijsko reakcijo na katera druga podobna zdravila, ki jih jemljete za uravnavanje vašega sladkorja v krvi.
Experience in NYHA class III-IV is still limited.
Izkušenj pri bolnikih v razredih III-IV po NYHA je še vedno malo.
Onglyza may have a negligible influence on the ability to drive and use machines.
Zdravilo Onglyza ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
They work by helping to control the level of sugar in your blood.
Ta zdravila delujejo tako, da pomagajo obvladovati raven sladkorja v krvi.
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
• v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni, vključno z insulinom, če ta zdravila ne zagotavljajo ustrezne urejenosti glikemije (glejte poglavja 4.4, 4.5 in 5.1 za podatke, ki so na voljo o različnih kombinacijah).
• If you forget to take a dose of Onglyza, take it as soon as you remember it.
• Če pozabite vzeti odmerek zdravila Onglyza, ga vzemite, čim se spomnite.
Event rate per 100 patient-yrs
Dogodki na 100 bolnik-let
The tablets contain lactose (milk sugar).
Tablete vsebujejo laktozo (mlečni sladkor).
Do not use this medicine if the package is damaged or shows signs of tampering.
Ne uporabljajte tega zdravila, če je pakiranje poškodovano ali kaže znake, da ga je že kdo odpiral.
Tablets must not be split or cut.
Tablet se ne sme lomiti ali rezati.
This is a medicine used to lower blood pressure.
• diltiazem; uporablja se za zniževanje krvnega pritiska.
No dose adjustment is recommended based solely on age (see also sections 5.1 and 5.2).
Odmerka ni treba prilagoditi samo zaradi starosti (glejte tudi poglavji 5.1 in 5.2).
Dipeptidyl peptidase 4 (DPP4) inhibitors, ATC code: A10BH03
Zaviralci dipeptidilpeptidaze 4 (DPP4), Oznaka ATC: A10BH03
A double dose should not be taken on the same day.
Na isti dan ne sme vzeti dveh odmerkov.
Frequency of adverse reactions by treatment regimen
Pogostnost neželenih učinkov glede na režim zdravljenja
If you take more Onglyza than you should If you take more tablets than you should, talk to a doctor straight away.
Če ste vzeli večji odmerek zdravila Onglyza, kot bi smeli Če vzamete več tablet, kot bi smeli, se takoj posvetujte z zdravnikom.
Clinical data described below suggest that the risk for clinically meaningful interactions with co-administered medicinal products is low.
Spodaj opisani klinični podatki kažejo, da je tveganje za klinično pomembno medsebojno delovanje med sočasno uporabo drugih zdravil majhno.
Metformin was uptitrated from 500 to 2000 mg per day as tolerated.
povečevanje odmerka metformina od 500 do 2000 mg dnevno kot je bil toleriran.
Patients experienced relief of symptoms after discontinuation of the medication and some experienced recurrence of symptoms with reintroduction of the same or another DPP4 inhibitor.
Bolnikom so simptomi po prenehanju jemanja zdravila izginili, nekaterim bolnikom pa so se simptomi znova pojavili po ponovni uvedbi istega ali drugega zaviralca DPP4.
When driving or using machines, it should be taken into account that dizziness has been reported in studies with saxagliptin.
V primeru vožnje ali upravljanja strojev treba upoštevati, da je bila v študijah saksagliptina opisana omotica.
Table 4 Primary and Secondary Clinical Endpoints by Treatment Group in the SAVOR Study*
Preglednica 4: Primarni in sekundarni klinični opazovani dogodki po terapevtski skupini v preskušanju SAVOR*
The European Medicines Agency has deferred the obligation to submit the results of studies with Onglyza in one or more subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Onglyza za eno ali več podskupin pediatrične populacije pri zdravljenju sladkorne bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Patients should be informed of the characteristic symptoms of acute pancreatitis; persistent, severe abdominal pain.
Bolniki morajo biti seznanjeni o značilnih simptomih akutnega pankreatitisa: dolgotrajna, huda bolečina v trebuhu.
If pancreatitis is suspected, Onglyza should be discontinued; if acute pancreatitis is confirmed, Onglyza should not be restarted.
Če se pojavi sum na pankreatitis, je potrebno ukiniti zdravljenje z zdravilom Onglyza; če je akutni pankreatitis potrjen, se zdravila Onglyza ne sme ponovno začeti uporabljati.
• if you have reduced kidney function, your doctor will decide if you need to take a lower dose of Onglyza.
• če imate zmanjšano delovanje ledvic, se bo zdravnik odločil ali potrebujete nižji odmerek zdravila Onglyza.
The effects of smoking, diet, herbal products, and alcohol use on the pharmacokinetics of saxagliptin have not been specifically studied.
Vplivi kajenja, prehrane, zdravil rastlinskega izvora in alkohola na farmakokinetiko saksagliptina niso posebej raziskani.
In the SAVOR study subgroups over 65 and over 75 years of age, efficacy and safety were consistent with the overall study population.
V preskušanju SAVOR sta se učinkovitost in varnost v podskupinah starejših od 65 in starejših od 75 let skladali s tistima v celotni preiskovani populaciji.
Events accumulated consistently over time, and the event rates for Onglyza and placebo did not diverge notably over time.
Dogodki so se skozi čas kopičili stalno in deleži dogodkov se z zdravilom Onglyza in placebom skozi čas niso občutno razhajali.
The findings of these studies were confirmed with two subsequent 24-week regional (Asian) monotherapy studies comparing saxagliptin 5 mg with placebo.
Ugotovitve teh študij so bile potrjene z dvema nadaljnjima 24-tedenskima regionalnima (Azija) študijama monoterapije, ki sta primerjali saksagliptin 5 mg s placebom.
Onglyza should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Zdravila Onglyza ne smete uporabljati pri bolnikih s sladkorno boleznijo tipa 1 ali za zdravljenje diabetične ketoacidoze.
During postmarketing experience, including spontaneous reports and clinical trials, the following adverse reactions have been reported with the use of saxagliptin: serious hypersensitivity reactions, including anaphylactic reaction, anaphylactic shock, and angioedema.
Iz izkušenj iz obdobja trženja, vključno s spontanimi poročili in kliničnimi preskušanji, so glede uporabe saksagliptina poročali o naslednjih neželenih učinkih: resnih preobčutljivostnih reakcijah, vključno z anafilaktično reakcijo, anafilaktičnim šokom, in angioedemom.
• if you suffer from heart failure or you have other risk factors for developing heart failure such as problems with your kidneys.
• če imate srčno popuščanje, ali imate kakšen drug dejavnik tveganja za pojav srčnega popuščanja, na primer težave z ledvicami.
In this study, 98.2% of the patients received other antihyperglycaemic treatments (75.3% on insulin and 31.2% on oral antihyperglycaemics; some received both).
V tej študiji je 98,2 % bolnikov prejemalo še druga antihiperglikemična zdravljenja (75,3 % insulin in 31,2 % peroralne antihiperglikemike; nekateri so prejemali oboje).
Onglyza should not be used during pregnancy unless clearly necessary.
Zdravila Onglyza ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.